Results 51 to 60 of about 35,844 (248)

Denosumab rapidly increases cortical bone in key locations of the femur: a 3D bone mapping study in women with osteoporosis. [PDF]

, 2014
Women with osteoporosis treated for 36 months with twice-yearly injections of denosumab sustained fewer hip fractures compared with placebo. Treatment might improve femoral bone at locations where fractures typically occur.
Brown, Jacques P, Gee, Andrew H, Libanati, Cesar, McClung, Michael R, Poole, Kenneth ES, Treece, Graham M, Wang, Andrea   +6 more
core   +2 more sources

Romosozumab and Denosumab Combination Therapy After Denosumab in Postmenopausal Osteoporosis

Arthritis &Rheumatology, Accepted Article.
Background Transition from long‐term denosumab to PTH‐analogs or romosozumab might expose patients to the risk of the so‐called rebound phenomenon. Adding romosozumab to denosumab might represent an option in patients experiencing a fracture while on denosumab.
Giovanni Adami, Francesco Pollastri, Angelo Fassio, Filippo Montanari, Anna Piccinelli, Camilla Benini, Emma Pasetto, Carmen Dartizio, Davide Gatti, Maurizio Rossini, Ombretta Viapiana   +10 more
wiley   +1 more source

Objective response of denosumab for multiple pulmonary metastases from giant cell tumor of bone: A case report and review of the literature

Current Problems in Cancer: Case Reports, 2021
A 23-year-old man received denosumab therapy for histologically proven multiple pulmonary metastases from a giant cell tumor of the distal femur after surgery.
Ikuo Kudawara, Shigeki Kakunaga, Koji Takami   +2 more
doaj   +1 more source

Biomechanical Computed Tomography analysis (BCT) for clinical assessment of osteoporosis. [PDF]

, 2020
The surgeon general of the USA defines osteoporosis as "a skeletal disorder characterized by compromised bone strength, predisposing to an increased risk of fracture." Measuring bone strength, Biomechanical Computed Tomography analysis (BCT), namely ...
Bouxsein, ML, Clarke, BL, Cosman, F, Keaveny, TM, Khosla, S, Orwoll, ES, Siris, ES   +6 more
core  

Activity of eribulin mesylate in brain metastasis from breast cancer. a stone in a pond? [PDF]

, 2018
Background: Brain metastases develop in approximately 10-25% of patients with metastatic breast cancer (MBC) and are associated with a very poor prognosis.
Catania, G., Cognetti, F., Fabi, A., Gasparro, S., Malaguti, P., Vidiri, A.   +5 more
core   +1 more source

Machine learning methods for predicting adverse drug events: A systematic review

British Journal of Clinical Pharmacology, EarlyView.
Abstract Predicting adverse drug events (ADEs) in outpatient settings is crucial for improving medication safety, identifying high‐risk patients and reducing health‐care costs. While traditional methods struggle with the complexity of health‐care data, machine learning (ML) models offer improved prediction capabilities; however, their effectiveness in ...
Niaz Chalabianloo, Fatemeh Ahmadi, Mohammad Ali Omrani, Sheikh S. Abdullah, Neda Rostamzadeh, Atefeh Jafari, Lujain Izzedin, Kamran Sedig, Flory T. Muanda   +8 more
wiley   +1 more source

Long-term effect of denosumab on bone microarchitecture as assessed by tissue thickness–adjusted trabecular bone score in postmenopausal women with osteoporosis: results from FREEDOM and its open-label extension [PDF]

, 2023
Didier Hans, Michele McDermott, Shuang Huang, Min Kim, Enisa Shevroja, Michael R. McClung   +5 more
openalex   +1 more source

Atypical femoral fracture in patients with bone metastasis receiving denosumab therapy: a retrospective study and systematic review

BMC Cancer, 2019
Background While denosumab has been shown to prevent skeletal-related events in patients with bone metastasis, there is a concern that it may cause atypical femoral fracture (AFF).
Momoko Takahashi, Yukinori Ozaki, Rika Kizawa, Jun Masuda, Kentaro Sakamaki, Keiichi Kinowaki, Taro Umezu, Chihiro Kondoh, Yuko Tanabe, Nobuko Tamura, Yuji Miura, Takashi Shigekawa, Hidetaka Kawabata, Noriyuki Baba, Haruo Iguchi, Toshimi Takano   +15 more
doaj   +1 more source

Rebound-associated vertebral fractures after denosumab discontinuation in a lung cancer patient with bone metastases

Bone Reports, 2022
Denosumab is a commonly used antiresorptive treatment in patients with osteoporosis or solid tumours with bone metastases. Upon denosumab discontinuation, a rebound phenomenon can occur that results in an increased (vertebral) fracture risk.
Jolan Dupont, Wesley Appermans, Marian Dejaeger, Isabelle Wauters, Michaël R. Laurent, Evelien Gielen   +5 more
doaj   +1 more source

Clinical pharmacology and prescribing education: An updated medical school curriculum from the British Pharmacological Society

British Journal of Clinical Pharmacology, EarlyView.
Aims Prescribing is a complex, essential skill that doctors must acquire to practice medicine safely and effectively. The British Pharmacological Society has historically provided a core curriculum to guide clinical pharmacology and prescribing education in UK medical schools.
Dagan O. Lonsdale, Clare Guilding, Jennifer Koenig, Michael Okorie, Reecha Sofat, Simon Maxwell   +5 more
wiley   +1 more source